A House committee is scheduled to vote on proposals that would tighten China-related investment and in-licensing restrictions for US biomedical activity. The package would consider additions such as BINSA research restrictions and support for domestic biomanufacturing, with the rules intended to address national security and supply-chain concerns. The deliberations reflect a broader congressional push to increase oversight of cross-border licensing and technology flows, particularly for biotechnology assets that could be considered strategic. For biotech business development teams and early-stage investors, the near-term impact is a potential shift in deal structuring, timing, and the permissibility of certain licensing models tied to China-originated assets and platforms.